Getting Defensive Now Real Money Pro($)

I am adding allocation to healthcare.
I would look to buy the weakness inside the $102.30-$100.59 zone.
Yesterday's action in the stock speaks volumes.
They are prone to being whipsawed by news.
Its hepatitis C drug will dominate the market.
Here's how to trade some key price relationships.

Gilead Is a Buying Opportunity Real Money Pro($)

Its hepatitis C drug is better; the stock trades at a discount.

Cytori Therapeutics Risk Play Real Money Pro($)

A high risk/high reward play.

In Defense of Gilead Sciences Real Money Pro($)

It has a great long-term future.
Has everyone buying the shares at runaway prices had enough yet?

Columnist Conversations

It's been a while since I have shown this chart. For the last 2 years the yields on the Five Year Note have tr...
Ugly end to a challenging week as stocks post around three percent declines for the opening month of 2015. Oil...


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.